HUP0300203A3 - Novel cyclic amide derivatives, and pharmaceutical compositions containing same - Google Patents

Novel cyclic amide derivatives, and pharmaceutical compositions containing same

Info

Publication number
HUP0300203A3
HUP0300203A3 HU0300203A HUP0300203A HUP0300203A3 HU P0300203 A3 HUP0300203 A3 HU P0300203A3 HU 0300203 A HU0300203 A HU 0300203A HU P0300203 A HUP0300203 A HU P0300203A HU P0300203 A3 HUP0300203 A3 HU P0300203A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
amide derivatives
containing same
cyclic amide
Prior art date
Application number
HU0300203A
Other languages
English (en)
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of HUP0300203A2 publication Critical patent/HUP0300203A2/hu
Publication of HUP0300203A3 publication Critical patent/HUP0300203A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0300203A 2000-02-29 2001-02-26 Novel cyclic amide derivatives, and pharmaceutical compositions containing same HUP0300203A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000054674 2000-02-29
PCT/JP2001/001413 WO2001064670A1 (fr) 2000-02-29 2001-02-26 Nouveaux derives amide cycliques

Publications (2)

Publication Number Publication Date
HUP0300203A2 HUP0300203A2 (en) 2003-05-28
HUP0300203A3 true HUP0300203A3 (en) 2006-01-30

Family

ID=18575896

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300203A HUP0300203A3 (en) 2000-02-29 2001-02-26 Novel cyclic amide derivatives, and pharmaceutical compositions containing same

Country Status (19)

Country Link
US (1) US7166617B2 (hu)
EP (1) EP1260512B1 (hu)
JP (1) JP4859324B2 (hu)
KR (1) KR100815772B1 (hu)
CN (1) CN100384836C (hu)
AT (1) ATE366249T1 (hu)
AU (2) AU3417501A (hu)
CA (1) CA2401711C (hu)
CY (1) CY1106858T1 (hu)
DE (1) DE60129210T2 (hu)
DK (1) DK1260512T3 (hu)
ES (1) ES2291293T3 (hu)
HU (1) HUP0300203A3 (hu)
IL (2) IL151533A0 (hu)
NZ (1) NZ521576A (hu)
PT (1) PT1260512E (hu)
RU (1) RU2257384C2 (hu)
TW (1) TWI296625B (hu)
WO (1) WO2001064670A1 (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057672A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
KR20060061393A (ko) * 2003-10-24 2006-06-07 에프. 호프만-라 로슈 아게 Ccr3 수용체 길항제
US20060019969A1 (en) * 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of allodynia
US8329694B2 (en) 2005-06-24 2012-12-11 Toyama Chemical Co., Ltd. Quinoxalinones as antibacterial composition
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
JP2009509921A (ja) * 2005-08-12 2009-03-12 アストラゼネカ アクチボラグ 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
MX2009005795A (es) 2006-12-11 2009-06-08 Reviva Pharmaceuticals Inc Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
WO2009010479A2 (en) * 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
CN103108548A (zh) * 2010-07-20 2013-05-15 昔勒尼药品公司 使用环酰胺衍生物治疗σ受体介导的病症的方法
TWI583679B (zh) * 2010-07-20 2017-05-21 田邊三菱製藥股份有限公司 使用環醯胺衍生物治療精神分裂症之方法
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
US10179776B2 (en) * 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
JP6761413B2 (ja) 2015-06-11 2020-09-23 富士フイルム富山化学株式会社 シグマ受容体結合剤
CN105523939B (zh) * 2015-12-30 2017-11-14 李函璞 一种来那度胺中间体的制备方法
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
EP3990113A1 (en) 2019-06-28 2022-05-04 Teva Czech Industries s.r.o. Solid state forms of roluperidone and salts thereof
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides
EP4196222A1 (en) 2020-08-14 2023-06-21 Minerva Neurosciences, Inc. Condensed azacycles as sigma ligand compounds and uses thereof
CN113651767B (zh) * 2021-09-18 2023-06-09 江西中医药大学 一种苯并异噁唑类杂环化合物及其制备方法和应用
WO2023154927A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3947578A (en) 1972-07-28 1976-03-30 Roussel Uclaf Omega-[4-(3"-indolyl)-piperidino]-alkyl-arylketones as nevroleptics
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4000287A (en) 1974-12-16 1976-12-28 Ciba-Geigy Corporation Isoindolinopiperidines
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4062953A (en) 1976-06-24 1977-12-13 E. R. Squibb & Sons, Inc. Various 2-substituted-1H-benz[de]isoquinoline-1,3(2H)-diones
US4168315A (en) 1977-09-28 1979-09-18 The Upjohn Company Dianisyl thiazole compound, compositions and method of antithrombotic treatment
US4495194A (en) 1982-11-12 1985-01-22 Mead Johnson & Company Antihypertensive isoindole derivatives
US4912117A (en) 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5021428A (en) 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4783471A (en) 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4762842A (en) 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
JP2660407B2 (ja) 1986-09-26 1997-10-08 住友製薬株式会社 新規なイミド誘導体
DE3855287T2 (de) * 1987-06-26 1996-12-05 Hitachi Ltd Supraleitender Draht
US4877798A (en) 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
US5166211A (en) 1987-12-17 1992-11-24 Merrell Dow Pharmaceuticals Inc. Method of using 1,4-disubstituted piperidinyl compounds in the treatment of coronary vasospasons and variant angina
US5093341A (en) 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
EP0339342A1 (de) 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
US5182399A (en) 1988-10-13 1993-01-26 Merrell Dow Pharmaceuticals Inc. Process for preparing piperidinyl benzimidazoles
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
FR2641278B1 (fr) 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
KR927002347A (ko) * 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
US5106855A (en) 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
US5292752A (en) 1989-12-21 1994-03-08 Merrell Dow Pharmaceuticals Inc. Antithrombotic compounds
JP2869512B2 (ja) 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド (+)―α―(2,3―ジメトキシフェニル)―1―[2―(4―フルオロフェニル)エチル]―4―ピペリジンメタノール
ATE145208T1 (de) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
EP0561973A1 (en) 1990-12-14 1993-09-29 Merrell Dow Pharmaceuticals Inc. Antiallergic compounds
US5231099A (en) 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
DE69330823T2 (de) 1992-02-13 2002-05-02 Merrell Pharma Inc Thiacyclische piperidinylderivate
JP2001509029A (ja) 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド ヒトタンパク質
DE19905823C1 (de) 1999-02-12 2000-06-08 Deutsches Krebsforsch Kollimator zum Begrenzen eines Bündels energiereicher Strahlen
CA2364739A1 (en) 1999-03-18 2000-09-21 Incyte Pharmaceuticals, Inc. Regulators of intracellular phosphorylation

Also Published As

Publication number Publication date
CN100384836C (zh) 2008-04-30
KR20020095185A (ko) 2002-12-20
NZ521576A (en) 2005-06-24
PT1260512E (pt) 2007-10-10
AU2001234175B2 (en) 2004-10-07
HUP0300203A2 (en) 2003-05-28
IL151533A (en) 2008-03-20
CA2401711A1 (en) 2001-09-07
US7166617B2 (en) 2007-01-23
AU3417501A (en) 2001-09-12
WO2001064670A1 (fr) 2001-09-07
EP1260512A4 (en) 2005-07-13
TWI296625B (en) 2008-05-11
RU2257384C2 (ru) 2005-07-27
DK1260512T3 (da) 2007-11-05
IL151533A0 (en) 2003-04-10
ATE366249T1 (de) 2007-07-15
ES2291293T3 (es) 2008-03-01
CY1106858T1 (el) 2012-05-23
DE60129210D1 (de) 2007-08-16
CN1426405A (zh) 2003-06-25
US20030212094A1 (en) 2003-11-13
DE60129210T2 (de) 2008-03-20
EP1260512A1 (en) 2002-11-27
EP1260512B1 (en) 2007-07-04
CA2401711C (en) 2008-06-03
JP4859324B2 (ja) 2012-01-25
KR100815772B1 (ko) 2008-03-20

Similar Documents

Publication Publication Date Title
HUP0300203A3 (en) Novel cyclic amide derivatives, and pharmaceutical compositions containing same
DZ3311A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
DZ3313A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
HUP0301146A3 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0400636A3 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
HUP0301113A3 (en) Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors, pharmaceutical compositions containing them and their use
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
AU2001234175A1 (en) Novel cyclic amide derivatives
HUP0302959A3 (en) Non-imidazole aryloxyalkylamines, pharmaceutical compositions containing them and their use
IL158898A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF
HUP0200996A3 (en) Amine derivatives, pharmaceutical compositions containing them and their use
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
HUP0401403A3 (en) 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
HUP0103530A3 (en) N,n-substituted cyclic amine derivatives and pharmaceutical compositions containing them
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
PL356911A1 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
HUP0401733A3 (en) Cyclic amine-derivatives and pharmaceutical compositions containing them
HUP0400806A3 (en) Heterocondensated(gamma)lactam derivatives, their use and pharmaceutical compositions containing them
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof